Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2121

1.

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS, Puga RD, Alves Paiva RM, Arcila ME, Hamerschlak N, Kantarjian HM, Levine RL, Campregher PV, Rampal RK, Verstovsek S.

Leukemia. 2019 Oct 18. doi: 10.1038/s41375-019-0603-9. [Epub ahead of print]

PMID:
31628430
2.

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.

Rambaldi A, Ribera JM, Kantarjian HM, Dombret H, Ottmann OG, Stein AS, Tuglus CA, Zhao X, Kim C, Martinelli G.

Cancer. 2019 Oct 18. doi: 10.1002/cncr.32558. [Epub ahead of print]

PMID:
31626339
3.

Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.

Srour SA, Saliba RM, Bittencourt MC, Ramos Perez JM, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO.

Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25647. [Epub ahead of print]

PMID:
31595538
4.

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.

Dalle IA, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F.

Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25648. [Epub ahead of print]

PMID:
31595534
5.

Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.

Rafei H, Kantarjian HM, Jabbour EJ.

Br J Haematol. 2019 Sep 30. doi: 10.1111/bjh.16207. [Epub ahead of print] Review.

PMID:
31566728
6.

Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders.

Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, Pudipeddi M, Nidarmarthy S, Vaddi K, Kantarjian H.

Haematologica. 2019 Sep 26. pii: haematol.2019.229583. doi: 10.3324/haematol.2019.229583. [Epub ahead of print]

7.

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2019 Sep 25. doi: 10.1002/cncr.32504. [Epub ahead of print]

PMID:
31553487
8.

Emerging drug profile: CPX-351 (vyxeos) in AML.

Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N.

Leuk Lymphoma. 2019 Sep 24:1-10. doi: 10.1080/10428194.2019.1660970. [Epub ahead of print]

PMID:
31547736
9.

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J.

Cancer Med. 2019 Sep 10. doi: 10.1002/cam4.2545. [Epub ahead of print]

10.

The many roads to universal health care in the USA.

Jones G, Kantarjian H.

Lancet Oncol. 2019 Oct;20(10):e601-e605. doi: 10.1016/S1470-2045(19)30517-0. Epub 2019 Aug 28. Review.

PMID:
31473128
11.

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.

Marks DI, van Oostrum I, Mueller S, Welch V, Vandendries E, Loberiza FR, Böhme S, Su Y, Stelljes M, Kantarjian HM.

Cancer Med. 2019 Oct;8(13):5959-5968. doi: 10.1002/cam4.2480. Epub 2019 Aug 22.

12.

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.

Jabbour EJ, Gökbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS.

Cancer. 2019 Aug 21. doi: 10.1002/cncr.32335. [Epub ahead of print]

PMID:
31433496
13.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C.

J Clin Oncol. 2019 Oct 10;37(29):2632-2642. doi: 10.1200/JCO.19.00416. Epub 2019 Aug 20.

PMID:
31430225
14.

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.

Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.

PMID:
31400961
15.

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.

Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD.

Am J Hematol. 2019 Aug 10. doi: 10.1002/ajh.25610. [Epub ahead of print] No abstract available.

PMID:
31400013
16.

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.

Chung W, Kelly AD, Kropf P, Fung H, Jelinek J, Su XY, Roboz GJ, Kantarjian HM, Azab M, Issa JJ.

Clin Epigenetics. 2019 Jul 22;11(1):106. doi: 10.1186/s13148-019-0704-3.

17.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F.

Cancer. 2019 Nov 1;125(21):3755-3766. doi: 10.1002/cncr.32387. Epub 2019 Jul 16.

PMID:
31310323
18.

SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.

Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):471-479. doi: 10.1016/j.clml.2019.06.011. Epub 2019 Jul 3. Review.

PMID:
31307896
19.

Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?

Sasaki K, Kantarjian HM, Jabbour EJ.

Cancer. 2019 Nov 1;125(21):3891-3892. doi: 10.1002/cncr.32385. Epub 2019 Jul 10. No abstract available.

PMID:
31291004
20.

Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia.

Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S.

Am J Hematol. 2019 Oct;94(10):E256-E259. doi: 10.1002/ajh.25571. Epub 2019 Jul 28. No abstract available.

PMID:
31273842
21.

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.

Rafei H, Jabbour EJ, Kantarjian H, Sinicrope KD, Kamiya-Matsuoka C, Mehta RS, Daver NG, Kadia TM, Naqvi K, Cortes J, Konopleva M.

Leuk Lymphoma. 2019 Jun 27:1-4. doi: 10.1080/10428194.2019.1633635. [Epub ahead of print] No abstract available.

PMID:
31246142
22.

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.

Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F.

Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553. [Epub ahead of print]

PMID:
31237017
23.

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Shih YT, Cortes JE, Kantarjian HM.

Lancet Haematol. 2019 Aug;6(8):e398-e408. doi: 10.1016/S2352-3026(19)30087-0. Epub 2019 Jun 14.

PMID:
31208943
24.

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.

Guerra VA, Jabbour EJ, Ravandi F, Kantarjian H, Short NJ.

Ther Adv Hematol. 2019 May 19;10:2040620719849496. doi: 10.1177/2040620719849496. eCollection 2019. Review.

25.

Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.

Kantarjian HM.

Clin Adv Hematol Oncol. 2019 May;17(5):268-270. No abstract available.

PMID:
31188803
26.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.

Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M.

Cancer. 2019 Sep 15;125(18):3219-3224. doi: 10.1002/cncr.32196. Epub 2019 May 31.

PMID:
31150121
27.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
28.

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.

Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H.

Leuk Lymphoma. 2019 May 24:1-9. doi: 10.1080/10428194.2019.1617862. [Epub ahead of print]

PMID:
31125272
29.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.

Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M.

Haematologica. 2019 May 23. pii: haematol.2018.205534. doi: 10.3324/haematol.2018.205534. [Epub ahead of print]

30.

Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.

Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD.

Br J Haematol. 2019 Aug;186(4):538-548. doi: 10.1111/bjh.15960. Epub 2019 May 22.

PMID:
31115909
31.

Recent advances in the treatment of acute lymphoblastic leukemia.

Rafei H, Kantarjian HM, Jabbour EJ.

Leuk Lymphoma. 2019 May 16:1-16. doi: 10.1080/10428194.2019.1605071. [Epub ahead of print]

PMID:
31092071
32.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A.

Blood Adv. 2019 May 14;3(9):1533-1539. doi: 10.1182/bloodadvances.2019031336.

33.

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR.

Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.

PMID:
31060979
34.

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M.

Cancer Cell. 2019 May 13;35(5):721-737.e9. doi: 10.1016/j.ccell.2019.03.014. Epub 2019 May 2.

PMID:
31056398
35.

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.

Marks DI, Kebriaei P, Stelljes M, Gökbuget N, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJ.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1720-1729. doi: 10.1016/j.bbmt.2019.04.020. Epub 2019 Apr 27.

36.

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M.

N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.

PMID:
31018069
37.

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Stein AS, Kantarjian H, Gökbuget N, Bargou R, Litzow MR, Rambaldi A, Ribera JM, Zhang A, Zimmerman Z, Zugmaier G, Topp MS.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1498-1504. doi: 10.1016/j.bbmt.2019.04.010. Epub 2019 Apr 17.

38.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM.

Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.

PMID:
30985931
39.

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F.

Am J Hematol. 2019 Jul;94(7):E188-E190. doi: 10.1002/ajh.25490. Epub 2019 Apr 29. No abstract available.

PMID:
30977182
40.

Treatment of relapsed/refractory acute lymphoblastic leukemia.

Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ.

Clin Adv Hematol Oncol. 2019 Mar;17(3):166-175. Review.

PMID:
30969955
41.

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0472-2. [Epub ahead of print]

PMID:
30967620
42.

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.

Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KP.

Am J Hematol. 2019 Jul;94(7):757-766. doi: 10.1002/ajh.25486. Epub 2019 May 7.

PMID:
30963592
43.

Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.

Dombret H, Topp MS, Schuh AC, Wei AH, Durrant S, Bacon CL, Tran Q, Zimmerman Z, Kantarjian H.

Leuk Lymphoma. 2019 Sep;60(9):2214-2222. doi: 10.1080/10428194.2019.1576872. Epub 2019 Apr 5.

PMID:
30947585
44.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G.

Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.

PMID:
30926081
45.

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS.

Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.

46.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G.

Blood Adv. 2019 Mar 26;3(6):922-933. doi: 10.1182/bloodadvances.2018026989.

47.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE.

Blood Adv. 2019 Mar 26;3(6):851-861. doi: 10.1182/bloodadvances.2018025874.

48.

Recent Advances in Adult Acute Lymphoblastic Leukemia.

Richard-Carpentier G, Kantarjian H, Jabbour E.

Curr Hematol Malig Rep. 2019 Apr;14(2):106-118. doi: 10.1007/s11899-019-00503-1. Review.

PMID:
30879177
49.

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.

Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian H, Garcia-Manero G.

Cancer. 2019 Mar 12. doi: 10.1002/cncr.32056. [Epub ahead of print]

PMID:
30861111
50.

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia.

Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJ.

Am J Hematol. 2019 Jun;94(6):E158-E160. doi: 10.1002/ajh.25454. Epub 2019 Mar 18. No abstract available.

PMID:
30838674

Supplemental Content

Loading ...
Support Center